Pricing Log in Create free account

MBX Biosciences, Inc. (MBX) vs NewAmsterdam Pharma Company N.V. (NAMS)

MBX Biosciences, Inc. and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. MBX Biosciences, Inc. and NewAmsterdam Pharma Company N.V. are of similar size ($2.5B and $2.4B). MBX Biosciences, Inc. has the higher net margin (0.00% vs −3,644.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, MBX Biosciences, Inc. leads on 9 and NewAmsterdam Pharma Company N.V. on 2.

Valuation

Metric MBX NAMS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 343.55 9.71
P/B 5.78 3.87 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 254.35 9.21
Earnings yield (4.86%) (10.89%) (33.15%)
Free cash flow yield (3.60%) (5.87%) (25.50%)

Profitability

Metric MBX NAMS Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (3,432.20%) 0.00%
Net margin 0.00% (3,644.21%) 0.00%
Free cash flow margin 0.00% (2,018.28%) 0.00%
Return on equity (33.17%) (36.81%) (56.36%)
Return on assets (31.25%) (34.16%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MBX NAMS Biotechnology median
Revenue growth (TTM) — (88.87%) 6.02%
EPS growth (last fiscal year) 59.11% 32.81% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MBX NAMS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 18.08 9.03 4.72
Net debt to EBITDA 3.82 2.83 0.96

Dividend

Metric MBX NAMS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MBX NAMS Biotechnology median
Market cap 2.44b 2.46b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack